D. Bareford

D. Bareford, S. Chakrabarti, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

S. le Cessie, A. Green, J. Falkenburg, 2004, Blood.

Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon

S. Akiki, D. Bareford, Sangam Hebballi, 2012, Journal of Clinical Pathology.

Day case management of sickle pain: 3 years experience in a UK sickle cell unit

D. Bareford, C. Knight, C. Wright, 2004, British journal of haematology.

Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus.

J. Stuart, D. Bareford, S. Baar, 1986, Journal of clinical pathology.

Effects ofhyperglycaemia andsorbitol accumulation on erythrocyte deformability indiabetes mellitus

D. Bareford, S. Baar, P. Jennings, 1986 .

Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor

G. Lip, A. Blann, M. Wadley, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Red cell exchange in sickle cell disease.

D. Bareford, S. Lawson, S. Oakley, 1999, Clinical and laboratory haematology.

Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers.

G. Lip, A. Blann, D. Bareford, 2000, British journal of haematology.

Remission induction in a Jehovah's Witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin

D. Bareford, S. Wiltshire, S. Narayanan, 2005, Transfusion medicine.

The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension

D. Bareford, I. Islim, D. Beevers, 1992, Journal of hypertension.

Increased non‐transferrin bound iron in plasma‐depleted SAG‐M red blood cell units

A. Blann, D. Bareford, P. Harrison, 2002, Vox sanguinis.

Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy.

D. Bareford, P. Harrison, S. Marwah, 1994, Journal of clinical pathology.

Endothelium‐dependent and endothelium‐independent vasodilatation of the cutaneous circulation in sickle cell disease

G. Lip, A. Blann, G. Lip, 2011, European journal of clinical investigation.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

J. D. van der Walt, P. Campbell, A. Green, 2005, The New England journal of medicine.

Vascular endothelial growth factor and platelets in primary (essential) thrombocythaemia

A. Blann, G. Caine, D. Bareford, 2005, British journal of haematology.

Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation

G. Lip, A. Blann, D. Bareford, 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Prognostic implications of leg ulcers from hydroxycarbamide therapy in patients with essential thrombocythaemia.

J. Thachil, D. Bareford, C. Baggott, 2012, Leukemia research.

Best practice in primary care pathology: review 2

C. Mcnulty, C. Bloxham, K. Kerr, 2006, Journal of Clinical Pathology.

Best practice in primary care pathology: review 3

T. Reynolds, P. Twomey, D. Bareford, 2006, Journal of Clinical Pathology.

Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity

A. Blann, G. Serjeant, D. Bareford, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

P. Campbell, A. Green, J. Marsden, 2005, The Lancet.

Splenic rupture as a consequence of dual malignant pathology: a case report

D. Bareford, P. Stonelake, F. Hoar, 2003, Journal of clinical pathology.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

E. Ejerblad, O. Linder, H. Vestergaard, 2013, Leukemia research.

Interferon α and zidovudine therapy in adult T‐cell leukaemia lymphoma: response and outcome in 15 patients

J. Cavenagh, E. Matutes, E. Matutes, 2001, British journal of haematology.

Thalassaemia in pregnancy.

D. Bareford, 1991, BMJ.

Chronic neutrophilic leukaemia.

D. Bareford, P. Jacobs, 1980, American journal of clinical pathology.

Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.

G. Lip, G. Lowe, R. Watson, 1996, Circulation.

Follow-up of normal individuals with a positive antiglobulin test.

G. Longster, L. Tovey, D. Bareford, 2009, Scandinavian journal of haematology.

A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia

E. Ejerblad, O. Linder, H. Vestergaard, 2013, British journal of haematology.

Angiotropic large cell lymphoma presenting as intestinal obstruction

E. Jones, D. Bareford, R. Ganesan, 2007, Annals of Hematology.

Speed of relapse in children with acute lymphoblastic leukaemia.

D. Bareford, C. Bailey, E. Robinson, 2009, Scandinavian journal of haematology.

Post‐Transfusion Thrombocytopenia: Its Duration in Splenic and Asplenic Individuals

D. Bareford, S. Hart, B. Boughton, 1990, Vox sanguinis.

Thrombocytopenia Following Routine Blood Transfusion: Micro‐Aggregate Blood Filters Prevent Worsening Thrombocytopenia in Patients with Low Platelet Counts

D. Bareford, S. Lim, B. Boughton, 1989, Vox sanguinis.

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia — a phase II study

D. Gozzard, A. Goldstone, A. Newland, 2005, Cancer Immunology, Immunotherapy.

The Medical Research Council PT1 Trial in Essential Thrombocythemia.

P. Campbell, A. Green, J. Reilly, 2004 .

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.

M. Leyland, K. Bayston, J. Cohen, 1992, The Journal of antimicrobial chemotherapy.

Ethnic background is a determinant of average warfarin dose required to maintain the INR between 3.0 and 4.5

A. Blann, D. Bareford, 2004, Journal of thrombosis and haemostasis : JTH.

Chronic myeloid leukaemia occurring in a patient with hairy cell leukaemia

D. Bareford, F. Wandroo, F. el-Jehani, 2000, Journal of clinical pathology.

Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count

A. Blann, G. Caine, D. Bareford, 2004, Platelets.

Factor V and factor VIII:V ratio as prognostic indicators in paracetamol poisoning

M. Hart, D. Bareford, A. Jones, 1995, The Lancet.

Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship to genotype.

G. Lip, A. Blann, D. Bareford, 2006, Thrombosis research.

Increased levels of soluble P-selectin correlate with iron overload in sickle cell disease

A. Blann, D. Bareford, S. Marwah, 2007, British journal of biomedical science.

Vitamin E correlates inversely with non‐transferrin‐bound iron in sickle cell disease

A. Blann, D. Bareford, D. Wheelwright, 2001, British journal of haematology.

Inappropriate use of laboratory services: long term combined approach to modify request patterns.

D. Bareford, D Bareford, A Hayling, 1990, BMJ.

A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia

E. Ejerblad, O. Linder, H. Vestergaard, 2012 .

Best practice in primary care pathology: review 1

C. Mcnulty, D. Bareford, W. S. Smellie, 2005, Journal of Clinical Pathology.

Act now against new NHS competition regulations

Geoffrey S. Lewis, M. McCartney, N. Pride, 2013, BMJ.

The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment

G. Lip, A. Blann, D. Bareford, 2005, British Journal of Ophthalmology.

Best practice in primary care pathology: review 1

C. Mcnulty, S. Mackenzie, D. Bareford, 2005, Journal of Clinical Pathology.

Performance indicators.

D. Bareford, 1989, Journal of clinical pathology.

Colonic carcinoma presenting as repeated episodes of enterobacter septicaemia during induction of remission in acute myeloblastic leukaemia

D. Bareford, B. Odeh, 2009, British medical journal.

Laboratory tests for monitoring prophylactic exchange transfusion in pregnancy complicated by sickle cell disease.

J. Stuart, D. Bareford, I. Franklin, 1988, Clinical and laboratory haematology.

Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, flt‐1, in haematological cancers: A comparison with breast cancer

G. Lip, A. Blann, M. Wadley, 2001, American journal of hematology.

JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera.

P. Campbell, A. Green, J. Marsden, 2005 .

Synthesis of polymers of Bence-Jones protein for use as molecular weight markers for sodium dodecyl sulphate-polyacrylamide gel electrophoresis.

J. Whicher, D. Bareford, 1975, Clinica chimica acta; international journal of clinical chemistry.

Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus.

J. Stuart, D. Bareford, S. Baar, 1986, Journal of clinical pathology.

Plasma cell leukaemia relapsing in the dermis.

D. Bareford, D. Pamphilon, D. Barnard, 1984, Acta haematologica.

Ethnic Differences in Patient Perceptions of Atrial Fibrillation and Anticoagulation Therapy: The West Birmingham Atrial Fibrillation Project

G. Lip, D. Bareford, S. Kamath, 2002, Stroke.

Guideline for investigation and management of adults and children presenting with a thrombocytosis

P. Campbell, A. Green, W. Erber, 2010, British journal of haematology.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.

E. Ejerblad, O. Linder, H. Vestergaard, 2014, Leukemia research.